Is Matinas BioPharma Holdings Inc (MTNB) overvalued? · rev $1.1M
Matinas BioPharma Holdings Inc (MTNB) is a biotechnology company listed on US.
This page asks whether Matinas BioPharma Holdings Inc (MTNB) looks expensive on cached numbers — not a short thesis.
Latest reported MTNB revenue for 2023-12-31 was $1.1M. Net income was -$22.9M. Revenue was down 65.6% from 2022-12-31 to 2023-12-31. MTNB currently screens at market cap $5.6M.
MTNB currently screens at market cap $5.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MTNB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MTNB stock page for the full model, not this heading.
Not investment advice.